The purpose of this study is to evaluate the safety and efficacy of an active drug in subjects with relapsing Multiple Sclerosis (RMS).
From 18 Years to 65 Years.
- Participant has diagnosis of relapsing remitting multiple sclerosis (RRMS) or
secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24
- Participant has cranial magnetic resonance imaging (MRI) demonstrating lesion(s)
consistent with multiple sclerosis (MS).
- Participant has evidence of physical disability according to Expanded Disability
Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.
- Participants must not have experienced or be recovering from a clinical MS relapse
within 6 months of Screening.